Has the Real MIS Revolution Finally Arrived?
Robotics, or computer-enhanced surgery, still has its skeptics. But a small group of start-up device companies are pushing forward, claiming that they represent a radically new--and better--way to do surgery. The dilemma for the small companies: to sell the concept behind robotics while, at the same time, competitively positioning their individual offerings.
You may also be interested in...
Tired of fighting each other in court, the two leading robotics companies have decided to render their IP differences moot through a merger.
Vigorous regulatory scrutiny is a given, but opinions vary about how much the companies’ respective PBM businesses present a major antitrust risk.
Few plans submitted to FDA’s oncology review divisions in the wake of the April 2022 draft guidance were deemed acceptable, with enrollment goals being the most common topic of agency feedback. However, representatives from FDA and industry say the regulatory demand for such plans is pushing sponsors to build diversity into clinical trial programs from the start.